Twist Bioscience partners with Lilly TuneLab for AI drug discovery
South San Francisco, Calif. - Twist Bioscience has entered into an agreement with Lilly TuneLab to supply antibody characterization data for the AI/ML drug discovery platform developed by Eli Lilly and Company, as per a press release. Twist will provide services for AbLab, an antibody developability prediction model, with TuneLab users ordering these services using preferred protocols.
TuneLab, an initiative aimed at connecting experimental data with AI-enabled drug discovery, allows companies to utilize prediction models for candidate molecule selection. Emily M. Leproust, CEO and co-founder of Twist Bioscience, emphasized that the quality of an AI model's output is heavily dependent on the quality of the data used for training.
Twist Bioscience, known for its scale and high-throughput capabilities, will generate consistent and reliable antibody characterization data necessary for training these models. Lilly TuneLab is a part of Lilly Catalyze360, which provides biotech startups with access to strategic capital, lab space, technology, and R&D capabilities.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
